Education
About Us
Working with TipRanks
Follow Us
Beth Hecht Insider Profile
11 Followers
Beth Hecht, Director at Neos Therapeutics, holds 1.39M shares in Xeris Pharmaceuticals (Ticker: XERS), holds 18.84K shares in Iterum Therapeutics (Ticker: ITRM), holds 9.05K shares in Aytu BioScience (Ticker: AYTU).
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
+59.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Beth Hecht holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 16, 2020 - Mar 16, 2021
Return:+200.00%
The most profitable trade made by Beth Hecht
Beth Hecht's Trading History
Neos Therapeutics
Mar 19, 2021
―
Uninformative Sell
―
$0.00
Xeris Pharmaceuticals
Feb 03, 2025
CLO and Corporate Secretary
Uninformative Buy
―
$5.91M
Iterum Therapeutics
Jun 15, 2023
Director
Uninformative Buy
17.60K
$26.00K
Aytu BioScience
Apr 12, 2021
Director
Uninformative Buy
―
$11.31K
List of latest transactions for each holding click on a transaction to see Beth Hecht's performance on stock
You May Also Like
Beth Hecht insider profile FAQ
What is the percentage of profitable transactions made by Beth Hecht?
The percentage of profitable transactions made by Beth Hecht is 67%.
What is the average return per transaction made by Beth Hecht?
The average return per transaction made by Beth Hecht is 59.50%.
What stocks does Beth Hecht hold?
Beth Hecht holds: NEOS, XERS, ITRM, AYTU stocks.
What was Beth Hecht’s latest transaction?
Beth Hecht latest transaction was an Uninformative Buy of ―.
What was Beth Hecht's most profitable transaction?
Beth Hecht’s most profitable transaction was an Informative Buy of XERS stock on March 16, 2020. The return on the trade was 200.00%.
What is Beth Hecht's role in Neos Therapeutics?
Beth Hecht's role in Neos Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.